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Abstract
Interleukin-1 receptor-associated kinase, IRAK, has been shown to activate NFUB in response to interleukin-1. We have
explored the involvement of IRAK in regulation of the interleukin-2 gene in the murine thymoma cell line EL4.NOB-1 by
examining its effect on interleukin-2 promoter-linked reporter gene expression, interleukin-2 gene transcription and
interleukin-2 protein production. Cells transfected with IRAK displayed high levels of phosphorylated IRAK, increased
interleukin-2 promoter-linked reporter gene expression (which was dependent on NFUB) and interleukin-2 gene
transcription. IRAK was unable, however, to increase interleukin-2 protein production. Overexpression of TRAF-6
induced similar responses and again failed to increase interleukin-2 protein production. A dominant negative TRAF-6
inhibited reporter gene expression and interleukin-2 protein production in response to both interleukin-1 and IRAK
transfection. Interleukin-1 treatment and IRAK or TRAF-6 transfection increased interleukin-2 mRNA production. Only
interleukin-1 treatment stabilised the induced transcripts with 50% being detectable at 20 h post induction. The interleukin-2
mRNA induced in IRAK- or TRAF-6-transfected cells was depleted by s 90% at 6 h post induction. These data implicate
IRAK and TRAF-6 in transcriptional regulation of interleukin-2 gene expression via NFUB, and provide direct evidence that
IRAK lies upstream from TRAF-6. Neither IRAK nor TRAF-6 participates in stabilisation of interleukin-2 mRNA which is
required for interleukin-2 protein production. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
IL-1 is a principal cytokine responsible for the in-
duction of mediators which orchestrate the immune
and in£ammatory responses. The potent proin£am-
matory e¡ects induced by IL-1 are co-ordinated by
the increased expression of a variety of IL-1-induci-
ble genes. Following engagement of IL-1 with its
receptor, signals are transduced intracellularly caus-
ing transcription factor activation and enhanced gene
expression. Two distinct IL-1 cell surface receptors
exist, an 80 kDa type I receptor (IL-1RI) [1] and a 68
kDa type II receptor (IL-1RII) [2]. The IL-1 signal is
transduced exclusively through IL-1RI [3]. IL-1RII
acts as a regulatory decoy molecule [4]. The existing
model of IL-1 receptor interaction involves the en-
gagement by IL-1 of its type I receptor with subse-
quent heterodimer formation between IL-1RI and
the IL-1 receptor accessory protein (IL-1RAcp).
This receptor complex transduces the IL-1 signal in-
side the cell.
An ubiquitous signal triggered in response to IL-1
is activation of the transcription factor NFUB. Re-
cent advances have identi¢ed two signal transducers
involved in this process: an IL-1 receptor-associated
kinase, IRAK [5^7], and TRAF-6, a member of the
TNF receptor-associated factor family [8]. Originally
detected as a serine/threonine protein kinase activity
which could be coprecipitated with IL-1RI from IL-
1-stimulated T cells [9], IRAK was subsequently
identi¢ed and shown to be required for IL-1-induced
NFUB activation [7]. TRAF proteins are primarily
involved in TNF receptor-mediated NFUB activation
[9^12]. TRAF-6 is structurally and functionally re-
lated to the ¢ve other characterised TRAF proteins.
However, it participates in IL-1- rather than TNF-
induced NFUB activation [8].
The current model of IL-1-induced NFUB activa-
tion involves signal transduction through a multipro-
tein complex in which the cytosolic protein MyD88,
a member of the IL-1 receptor family, acts as an
adaptor coupling the receptor complex to IRAK
and IRAK-2 [13^17]. It has been proposed that the
IL-1 signal is relayed from IRAK and IRAK-2
through TRAF-6 to the kinase complex TAB1/
TAK1 which then activates NFUB-inducing kinase
(NIK), the upstream regulator of the IUB kinases,
IKK1 and IKK2 [18^23]. IUB becomes phosphoryl-
ated and releases NFUB which translocates to the
nucleus and induces target gene expression.
In this study, we have examined in detail the role
played by IRAK and TRAF-6 in the regulation of
the IL-2 gene in the murine thymoma cell line EL4.-
NOB-1. Several responses are induced in this cell line
by IL-1, including activation of transcription factors,
MAP kinase cascades and the production of IL-2.
We con¢rm that NFUB activation by IL-1 is regu-
lated by IRAK and TRAF-6 in these cells and show
that both proteins are critical for IL-2 promoter
function and IL-2 gene transcription. The e¡ects of
IRAK and TRAF-6 on IL-2 production are re-
stricted to transcription, however, and neither is
able to stabilise the mRNA transcript for IL-2.
Such stabilisation must therefore be required for
IL-2 protein production and is regulated in response
to IL-1. The results imply that IRAK and TRAF-6
only participate in the regulation of IL-2 gene tran-
scription by IL-1. Additional IL-1-induced signals
including IL-2 mRNA stabilisation are required,
without which no IL-2 protein production will occur.
2. Materials and methods
2.1. Materials
The EL4.NOB-1 cell line was obtained from the
European Collection of Animal Cell Cultures (Salis-
bury, UK). RPMI 1640 medium and foetal calf se-
rum were from HyClone Europe (Cramlington, UK).
Penicillin/streptomycin and L-glutamine (2 mM ¢nal
concentration) were purchased from Life Technolo-
gies. Human recombinant IL-1K was a gift from
Prof. J. Saklatvala (Kennedy Institute of Rheumatol-
ogy, London, UK). [14C]Chloramphenicol (54 mCi/
mmol) and [K-32P]dATP (triethylammonium salt,
3000 Ci/mmol) were from Amersham International
(Aylesbury, UK). Restriction enzymes, DNA modi-
fying enzymes, dNTPs, CIP and ECL LumiGlo re-
agent and peroxide were from NEB (Hertfordshire,
UK). Agarose, actinomycin D (C1), Rapid DNA li-
gation, Titan RT-PCR and First strand cDNA syn-
thesis kits were purchased from Boehringer Mann-
heim (East Sussex, UK). Oligonucleotide primers
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were from MWG Biotech (Milton Keynes, UK).
Prime-a-Gene kit was from Promega (Madison,
WI, USA). The (NFUB)5-linked CAT reporter plas-
mid was from Dr. T. Bird (Immunex, Seattle, WA,
USA), the IL-2 promoter-CAT plasmid was a gift
from Dr. W. Falk (University of Regensburg, Ger-
many). Anti-IRAK antiserum, plasmid pRK5 (empty
vector) and the IRAK, TRAF-6 and TRAF-6v ex-
pression plasmids were generously supplied by Dr.
D.V. Goeddel (Tularik, San Francisco, CA, USA).
Puri¢ed murine anti-IL-2, recombinant murine IL-2
and biotinylated murine anti-IL-2 were supplied by
Pharmingen (San Diego, CA, USA). CytoXpress
quantitative PCR kit for mouse IL-2 was from Bio-
Source International (Camarillo, CA, USA). All oth-
er materials were from Sigma (Poole, UK).
2.2. Cell culture and transfection
EL4.NOB-1 cells were cultured in RPMI 1640
containing 10% foetal calf serum, 2 mM L-glutamine,
penicillin and streptomycin and were maintained at
37‡C in a humidi¢ed atmosphere of 5% CO2. The
cells were transfected with indicated amounts of ex-
pression plasmid and 10 Wg of reporter plasmid. In
dose-response experiments the concentration of
DNA was maintained constant by supplementation
with pRK5. Brie£y, 1.4U107 cells were incubated
with plasmid DNA in TBS (25 mM Tris, pH 7.4,
137 mM NaCl, 5 mM KCl, 0.5 mM MgCl2, 0.6
mM NaH2PO4) containing 3 Wg DEAE dextran
and 50 Wg chloroquine for 30 min. The cells were
washed in RPMI 1640 containing 5 U/ml heparin.
Following two additional washes with medium, cells
were left to recover for 16 h in medium supplemented
with 20% FCS. Aliquots of cells were treated for
further time periods with human recombinant IL-
1K (10 ng/ml) or actinomycin D (1 mM) before har-
vesting cell extracts, RNA or culture supernatants.
2.3. Western blotting
Cells (5U106) were washed with 1 ml ice cold PBS
and suspended in 100 Wl extraction bu¡er (1% (v/v)
Triton X-100, 20 mM Tris acetate, pH 7, 0.1 mM
EDTA, 0.1 mM EGTA, 5 mM tetrasodium pyro-
phosphate, 270 mM sucrose, 10 mM benzamidine,
1 mM phenylmethylsulphonyl £uoride, 2 Wg/ml apro-
tinin and 1 Wg/ml leupeptin). Following a 15 min
incubation on ice the samples were centrifuged at
14 000Ug for 10 min at 4‡C. The protein concentra-
tion of the supernatants was determined [24] and
aliquots containing 2.5 Wg of protein were left un-
treated or incubated with 1 U CIP for 30 min at
37‡C. Samples were mixed with 2ULaemmli sample
bu¡er, boiled for 5 min and electrophoresed on 10%
SDS-polyacrylamide gels. The proteins were trans-
ferred to nitrocellulose ¢lters and these were blocked
in PBS, 0.05% Tween containing 5% (w/v) non-fat
milk. IRAK expression was detected using rabbit
polyclonal anti-IRAK antibodies (1:1000). The ¢lters
were washed and incubated with protein A peroxi-
dase (1:1000). Signals were developed using en-
hanced chemiluminescence (ECL).
2.4. CAT assays
Cells were harvested at 150Ug for 10 min and
washed twice in 1 ml PBS, then pelleted by centrifu-
gation at 14 000Ug for 5 min. Cell pellets were re-
suspended in 0.25 M Tris-HCl, pH 8 and lysed by
three cycles of freezing in liquid N2 and thawing at
37‡C. Protein concentration in each cell extract was
determined by the Bradford method [24]. Extracts
containing 20 Wg protein were incubated at 37‡C
overnight in bu¡er containing 1 mM acetyl-CoA
and 0.3 mCi [14C]chloramphenicol. The reactions
were stopped by addition of 350 Wl ethyl acetate,
vortexed for 30 s and the phases separated by cen-
trifugation at 14 000Ug for 1 min. The upper phase
was transferred to a fresh tube, vacuum dried and
suspended in 12 ml ethyl acetate. Acetylated and
non-acetylated complexes were resolved by silica gel
TLC in 19:1 (v/v) chloroform:methanol. The sepa-
rated products were quanti¢ed using image analysis
(InstantImager, Packard Instrument, Meriden, CT,
USA).
2.5. Measurement of IL-2 production
IL-2 was measured from total cell extracts (see
Section 2.3) or the supernatants of control and trans-
fected cells (1U106) which had been left untreated or
stimulated with IL-1K (10 ng/ml) for 24 h. It was not
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necessary to select stable transfectants as transfection
e⁄ciencies of s 80% were routinely obtained. IL-2
was measured by ELISA. Microtitre plates were
coated with anti-mouse IL-2 (4 Wg/ml in 0.1 M
NaHCO3, pH 8.2). Additional binding sites were
blocked with PBS/10% FCS and the plates washed
with PBS containing 1% Tween. Standards and sam-
ples, 100 Wl, were added and following washes were
incubated with anti-IL-2 (2 Wg/ml in PBS/10% FCS)
and avidin peroxidase (2.5 Wg/ml in PBS/10% FCS).
Signals were detected following addition of substrate
(300 ng/ml 2,2P-azino-bis(3-ethylbenzthiazoline-6-sul-
phonic acid) in 100 mM citric acid, pH 4.35, contain-
ing 0.03% H2O2) by measuring absorbances at 405
nm.
2.6. RNA extraction and analysis
Total RNA was isolated from 5U106/ml control
or transfected cells, which had been left untreated,
were stimulated with IL-1K (10 ng/ml) for 6 or 24 h
or to which actinomycin D (1 WM) was added for 3,
6 or 24 h, using TRI reagent according to the man-
ufacturer’s instructions. All RNA samples were
treated with 50 U RNase-free DNase for 30 min at
37‡C. Initially RT-PCR reactions (Titan, Boehringer
Mannheim) were performed as described in the man-
ufacturer’s protocol using oligonucleotide primers 5P-
AAGCTCCACTTCAAGCTCTACAGCG-3P (for-
ward) and 5P-TTGACAGAAGGCTATCCATCTC-
CTC-3P (reverse) to amplify a 412 bp product from
the IL-2 transcript and 5P-TTCCACGAGACACTG-
TACCAGAAGG-3P (forward) and 5P-ACCATGTT-
GGGCTTCAGCAATG-3P (reverse) to amplify a
464 bp product from the control aldolase transcript.
Thermocycling conditions were as follows: 50‡C for
30 min, 94‡C for 2 min; ten cycles of 94‡C for 30s,
55‡C for 30 s and 68‡C for 1 min; 25 cycles of 94‡C
for 30 s, 55‡C for 30 s and 68‡C for 1 min plus 5 s/
cycle and were carried out in a thermocycler from
MJ Research (Watertown, MA, USA). A ¢nal exten-
sion step of 68‡C for 7 min was followed by resolu-
tion of the products on a 1.5% TAE agarose gel
containing 0.5 Wg/ml ethidium bromide. The relative
amount of IL-2 and aldolase transcript in each sam-
ple was determined semi-quantitatively following
analysis by UVP transillumination densitometry
scanning and Gelworks 1D Advanced software.
RNA degradation was estimated by quantitation of
RT-PCR products blotted onto nylon membranes
and hybridised to K-32P random primer labelled IL-
2 or aldolase cDNAs. The signals were quantitated
using image analysis (InstantImager, Packard Instru-
ment) and normalised for the amount of aldolase
mRNA present.
For competitive IL-2 PCR reactions, 1 Wg RNA
was reverse transcribed into cDNA according to the
manufacturer’s instructions (Boehringer Mannheim).
The integrity of RNA extraction and cDNA synthe-
sis was veri¢ed by measuring the amount of aldolase
cDNA in each sample. Conditions for quantitative
competitive PCR were determined by carrying out
titration curves for IL-2 cDNAs and internal calibra-
tion standards (ICS) in PCR reactions as described
in the manufacturer’s protocol (BioSource Interna-
tional). This is a recently developed method which
allows quantitative measurements of murine IL-2
mRNA. The ICS template contained PCR primer
binding sites identical to the IL-2 cDNA which gen-
erated a 327 bp ICS product following PCR ampli-
¢cation. This was easily distinguishable by agarose
gel electrophoresis from the 277 bp IL-2 PCR prod-
uct. Microplate detection analysis using ICS- and IL-
2-speci¢c capture oligonucleotides bound to micro-
titre plate wells was carried out to determine the
amounts of biotin-labelled ICS and IL-2 amplicons.
In order to acquire quantitative results over a broad
range, denatured amplicons were analysed by serial
dilutions. PCR products were detected and quanti-
¢ed by addition of streptavidin-HRP followed by
substrate and measurement of optical density (OD)
at 450 nm. The number of copies of IL-2 cDNA in
each sample was calculated from the ratio of the
total IL-2 OD to the total ICS OD and the input
copy of the ICS.
RT-PCR was used to con¢rm expression of the
transfected cDNAs using the IRAK-speci¢c primers
5P-AGCAGAGCAGCTGCAGAGA-3P (forward)
and 5P-GGTGAAGACATCAGCTCT-3P (reverse)
to amplify a 427 bp fragment of the IRAK tran-
script, and the TRAF-6-speci¢c primers 5P-CATGC-
GCTTGCACCTTCA-3P (forward) and 5P-CTATA-
CCCCTGCATCAGT-3P (reverse) to amplify a 399
bp fragment of the TRAF-6 or TRAF-6v transcripts.
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3. Results
3.1. IRAK and TRAF-6 induce NFUB-linked reporter
gene expression in EL4.NOB-1 cells
IRAK activity has previously been detected in EL4
and 293 cells following stimulation with IL-1 [6,7]. In
293 cells coexpressing IL-1RI and IL-1RAcp two
species of IRAK can be detected by immunoblotting,
an 80 kDa unphosphorylated inactive form and a
100 kDa active phosphorylated form [15]. We exam-
ined IRAK expression in EL4.NOB-1 cells trans-
fected with a human IRAK cDNA by Western blot-
ting using anti-human IRAK antibodies. This was
carried out on extracts from control and IL-1-treated
cells (Fig. 1A). The transfected cells expressed detect-
able levels of IRAK. Both in the absence and pres-
ence of IL-1 stimulation, most of the IRAK was
detected at a molecular mass of 100 kDa (Fig. 1A,
lanes 1 and 2). This corresponded to phosphorylated
IRAK since treatment of extracts from control and
IL-1-stimulated cells with calf intestinal phosphatase
converted the 100 kDa form into an 80 kDa protein,
whose molecular mass corresponded to dephos-
phorylated IRAK (Fig. 1A, lanes 3 and 4). A band
of 75 kDa was detected but this was seen in non-
transfected cells and was of unknown identity (not
shown).
We next tested whether IRAK overexpression
would increase the expression of an NFUB-linked
reporter gene in EL4.NOB-1 cells. As shown in
Fig. 1B, in control cells the NFUB-CAT reporter
gene was activated greater than 4-fold over control
following stimulation with IL-1. Transfection with
the IRAK cDNA induced reporter gene expression
in the absence of IL-1, with 10 Wg of expression
plasmid inducing a maximum e¡ect of 5-fold over
control. Addition of IL-1 to the cells overexpressing
IRAK showed only a marginal increase over un-
treated transfected cells indicating that IRAK expres-
sion alone optimally activated NFUB. This was con-
sistent with our observation shown in Fig. 1A, where
overexpression of IRAK results in its activation, as
indicated by phosphorylation. Even doses of IRAK
cDNA as low as 0.5 Wg induced optimal responses.
At a dose of 20 Wg the activating e¡ects induced by
IRAK overexpression were abolished both in the ab-
sence and presence of IL-1 stimulation because of
Fig. 1. IRAK overexpression induces NFUB-linked gene expres-
sion. (A) Detection of IRAK in transfected cells. Protein ex-
tracts (2.5 Wg) from control (lanes 1 and 3) and IL-1-stimulated
cells (10 ng/ml) (lanes 2 and 4) which had been transfected with
an IRAK expression plasmid were left untreated (lanes 1 and
2) or incubated with CIP (1 U) at 37‡C for 30 min (lanes 3
and 4). Proteins were separated by 10% SDS-PAGE, transferred
to nitrocellulose and immunoblotted with antiserum to IRAK.
Reactive proteins of 80 kDa and 100 kDa were detected by
ECL. Molecular masses are indicated in kilodaltons. (B,C)
EL4.NOB-1 cells were transfected with an (NFUB)5-linked CAT
reporter plasmid (10 Wg) along with IRAK (B) and/or IUB
S32A/S36A mutant (C) expression plasmids as indicated. Fol-
lowing recovery (16 h) cells (1U106 per sample) were stimulated
with IL-1 (10 ng/ml) for 24 h or left untreated as shown. The
CAT reporter gene activity of samples containing 20 Wg protein
was determined by measuring % acetylation of an acetyl-CoA
substrate by [14C]chloramphenicol. Acetylated complexes were
resolved by silica gel TLC and quanti¢ed using image analysis.
The data represent the mean þ S.D. from triplicate determina-
tions and are expressed as relative activities compared to indi-
vidual controls. Similar results were obtained in at least two
further experiments.
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toxicity. This was not as a result of DNA toxicity
since control samples were una¡ected at similar
DNA concentrations. Therefore it appears that
when expressed at high concentrations IRAK can
induce killing of EL4.NOB-1 cells.
We also con¢rmed that the reporter construct
being used was driven by NFUB by cotransfecting
cells with a gene encoding an IUBK mutant in which
serines at positions 32 and 36 are both mutated to
alanines (IUB S32/36A). The resulting mutant protein
complexes with NFUB, preventing it activation, as
described in [25]. As can be seen in Fig. 1C, expres-
sion of this mutant prevented both IL-1- and IRAK-
induced NFUB-linked reporter gene expression, con-
¢rming that the e¡ect of IL-1 and IRAK on the
construct were speci¢c for NFUB.
3.2. Expression of IRAK activates the IL-2 promoter
We next examined the e¡ects of IRAK on an IL-1-
responsive gene promoter which can be activated in
EL4.NOB-1 cells, the murine IL-2 promoter up to
3273. This carries response elements for NFUB,
AP1 and NFAT, amongst others [26].
As shown in Fig. 2A expression of IRAK induced
a 4.5-fold activation of the reporter gene. The con-
trol empty vector, pRK5, had no e¡ect. Following
treatment with IL-1, transcription from the IL-2 pro-
moter was stimulated 2.5-fold. Addition of IL-1 to
cells expressing IRAK did not enhance the 4.5-fold
potentiation seen following IRAK expression in the
absence of IL-1, again indicating that overexpressed
IRAK is optimally active. Cotransfection of the
S32A/S36A mutant of IUB completely blocked the
increase in reporter gene expression con¢rming the
critical dependence of this reporter construct on
NFUB for responses induced by IL-1 and IRAK.
3.3. IRAK does not increase IL-2 protein production
We next assessed whether expression of IRAK
would also increase IL-2 protein production. Typi-
cally, we achieved 80% transfection e⁄ciency in
EL4.NOB-1 (as measured by FACS analysis of cells
expressing a rat CD2 construct; not shown). It is
therefore possible to measure IL-2 protein produc-
tion by ELISA in transfected cells. Intriguingly, we
found no e¡ect on IL-2 production upon transfection
of cells with IRAK, as shown for 10 Wg of IRAK-
encoding plasmid in Fig. 2B. IL-1 increased IL-2
production 4-fold in the cells. This response was un-
a¡ected by transfection of the cells with 1, 5 or 10 Wg
Fig. 2. E¡ect of IRAK on IL-2 promoter activation and IL-2
protein production. (A) EL4.NOB-1 cells were transfected with
an IL-2 promoter-linked CAT reporter plasmid (10 Wg), pRK5
(empty vector), IRAK and/or IUB S32A/S36A expression plas-
mids (10 Wg) as indicated. Following recovery (16 h) cells
(1U106 per sample) were left untreated or stimulated with IL-1
(10 ng/ml) for 24 h. The CAT reporter gene activity of samples
containing 20 Wg protein was determined by measuring % acety-
lation of an acetyl-CoA substrate by [14C]chloramphenicol. (B)
Supernatants were removed or (C) cell extracts were isolated,
these were assayed for IL-2 by ELISA as described. The data
represent the mean þ S.D. from triplicate determinations and
are expressed as relative activities compared to individual con-
trols (A), IL-2 production in ng/106 cells (B) or pg/106 cells
(C). Similar results were obtained in at least two further experi-
ments.
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pRK5 control plasmid. Addition of IL-1 to IRAK-
expressing cells caused a dose-dependent potentiation
in these responses however, resulting in a maximum
7-fold increase in IL-2 production. These results sug-
gested that additional IL-1 signals were required to
induce IL-2 protein production with IRAK partici-
pating in the pathway by regulating NFUB.
In order to address the identity of such signals we
¢rst examined secretion of IL-2, as it was possible
that IRAK increased IL-2 protein production, but
that an additional signal was required to induce se-
cretion. We therefore measured the total cellular lev-
els of IL-2 produced from each population of cells.
IRAK expression did not lead to an increase in cell-
associated IL-2, as shown in Fig. 2C. Following
treatment with IL-1 (10 ng/ml for 24 h) the levels
of IL-2 detectable in each cell lysate were elevated
compared to untreated samples, and a potentiation
in the response was observed in cells transfected with
10 Wg of IRAK-encoding plasmid. This result implied
that IRAK did not induce an increase in IL-2 protein
while failing to induce IL-2 secretion.
3.4. E¡ect of TRAF-6 on IL-2 gene expression
The results with IRAK implied that it was capable
of inducing IL-2 gene expression but was unable to
increase IL-2 protein production. Since TRAF-6 oc-
curs downstream from IRAK on the pathway to
NFUB we next determined whether a similar phe-
nomenon would apply to TRAF-6. Transfection of
cells with TRAF-6 cDNA induced NFUB-linked re-
porter gene expression in a dose-dependent manner
(Fig. 3A). The e¡ect of 0.5 and 1 Wg of TRAF-6-
encoding plasmid was potentiated by IL-1 to an op-
timum level of 6-fold over control. Furthermore, 20
Wg of TRAF-6 was not toxic to the cells, unlike that
observed with IRAK at this plasmid concentration,
implying that the toxicity observed with IRAK was
not due to a non-speci¢c e¡ect of recombinant pro-
tein overexpression.
TRAF-6 expression also increased IL-2 promoter-
linked reporter gene expression in a similar manner
to IL-1, 2.5-fold over control levels (Fig. 3B). This
was dependent on NFUB as the IUBK mutant again
inhibited this response (Fig. 3B). Similar to IRAK,
TRAF-6 expression was unable to induce IL-2 pro-
tein production (Fig. 3C). The e¡ect of IL-1 was
however potentiated in TRAF-6-transfected cells,
particularly at 10 Wg of TRAF-6 cDNA, where
over 7 ng/106 cells IL-2 was induced, compared to
Fig. 3. E¡ect of TRAF-6 on NFUB- and IL-2 promoter-linked
reporter gene expression and IL-2 protein production. EL4.-
NOB-1 cells were transfected with pRK5, TRAF-6 and IUB
S32A/S36A expression plasmids and NFUB- or IL-2 promoter-
linked CAT reporter plasmids as indicated. Following recovery
(16 h) cells (1U106 per sample) were stimulated with IL-1 (10
ng/ml) or left untreated. The NFUB-CAT (A) or IL-2 pro-
moter-linked CAT (B) gene activity of samples containing 20
Wg protein was determined by measuring % acetylation of an
acetyl-CoA substrate by [14C]chloramphenicol. Supernatants
were removed (C) and were assayed for IL-2 by ELISA as de-
scribed. The data represent the mean þ S.D. from triplicate de-
terminations and are expressed as relative activities compared
to individual controls (A,B) or IL-2 production in ng/106 cells
(C). Similar results were obtained in at least two further experi-
ments.
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4 ng/106 cells in IL-1-treated cells transfected with
the empty vector (Fig. 3C).
We also tested the e¡ect of TRAF-6v, a dominant
negative mutant of TRAF-6 in which the entire zinc-
binding domain of TRAF-6 is deleted, on IL-1 and
IRAK responses. This has been shown to suppress
IL-1-stimulated NFUB activation in 293 cells [8,27].
In response to IRAK transfection the relative activ-
ities of NFUB- and IL-2 promoter-linked reporter
gene expression were inhibited 60.3 þ 4.1% and
87 þ 3.3% respectively by TRAF-6v expression, pro-
viding direct evidence that TRAF-6 lies downstream
from IRAK. In addition, expression of TRAF-6v
blocked all of the responses to IL-1 in EL4.NOB-1
cells. IL-1-induced NFUB-CAT and IL-2 promoter-
CAT activities were inhibited 64 þ 3.9% and
74 þ 0.4%, respectively. Inhibition of 50 þ 8.8% was
achieved in IL-2 protein production by TRAF-6v.
This implicates TRAF-6 as an important signal
transducer of the IL-1 pathway leading to IL-2
gene transcription and protein production in T cells.
Overall, these results therefore implied that similar
to IRAK, TRAF-6 increases IL-2 gene transcription,
but is unable to induce subsequent events required
for IL-2 protein production.
C
Fig. 4. E¡ect of IL-1, IRAK and TRAF-6 on IL-2 mRNA ac-
cumulation and decay. EL4.NOB-1 cells were transfected with
pRK5, IRAK or TRAF-6 expression plasmids (10 Wg). Follow-
ing recovery (16 h) cells (5U106 per sample) were stimulated
with IL-1 (10 ng/ml for 6 h) or left untreated at which point
RNA extractions were performed. (A,B) Duplicate samples
were treated with actinomycin D (1 WM) for a further 6 h. The
levels of IL-2 mRNA were estimated by RT-PCR using IL-2-
speci¢c primers in reactions containing 1 Wg total RNA as tem-
plate. Control reactions measured levels of aldolase mRNA.
(A) Products were electrophoresed in 1.5% TAE agarose gels
containing 0.5 Wg/ml ethidium bromide, visualised under UV
and quanti¢ed by densitometry. (B) The RT-PCR products
were capillary blotted onto nylon membranes and probed with
K-32P-labelled IL-2 and aldolase cDNAs. The signals were
quanti¢ed using image analysis (InstantImager, Packard Instru-
ment) and normalised for the amount of aldolase mRNA
present. Results from three experiments (mean þ S.D.) are
shown in the lower panel of B. (C) Additional samples were
treated with actinomycin D (1 WM) for 3, 6 or 24 h prior to
RNA extraction. 1 Wg amounts of RNA were reverse tran-
scribed into cDNA and used as templates in PCR reactions
containing a known quantity of exogenously synthesised com-
petitive IL-2 cDNA (ICS), using biotinylated IL-2-speci¢c pri-
mers. The levels of IL-2 and ICS cDNA were quanti¢ed by
ELISA using capture IL-2- or ICS-speci¢c oligonucleotides
bound to microtitre wells. The PCR products were quanti¢ed
spectrophotometrically at 450 nm following addition of strepta-
vidin-HRP and substrate. The number of copies of IL-2
mRNA were calculated from the ratio of total IL-2 optical den-
sity:total ICS optical density and the input number of ICS
(2000 copies). Results are expressed as the mean þ S.D. (n = 3)
of relative IL-2 mRNA amounts. At 6 h IL-1 vs. IRAK and
TRAF-6, P = 0.0003 and 0.0001 (**), respectively (t-test). At
24 h IL-1 vs. IRAK or TRAF-6, P6 0.0001 (***).
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3.5. E¡ects of IL-1, IRAK and TRAF-6 on IL-2
mRNA production and stability
Considering that IRAK and TRAF-6 expression
increased IL-2 promoter-linked reporter gene expres-
sion but failed to increase IL-2 protein levels we next
investigated their e¡ects on IL-2 mRNA expression.
RT-PCR using IL-2 speci¢c primers was performed
on RNA samples isolated from control cells and cells
transfected with IRAK or TRAF-6 cDNAs (a repre-
sentative result is shown in Fig. 4A). The relative
amount of IL-2 transcript in each sample was deter-
mined semi-quantitatively by densitometry. The
amounts of IL-2 and aldolase RNA were also quan-
titated by instant imaging following Southern blot-
ting of the RT-PCR gels onto nylon membrane and
probing with K-32P-labelled IL-2- and aldolase-spe-
ci¢c probes (a representative result is shown in Fig.
4B). The steady state level of IL-2 mRNA was low in
unstimulated EL4.NOB-1 cells (Fig. 4A,B, lane 1).
Expression of IRAK and TRAF-6 induced IL-2
gene transcription 2.5 þ 0.1 and 1.6 þ 0.3-fold above
control (mean þ S.D., n = 3), respectively (lanes 5 and
7). IL-1 treatment (10 ng/ml for 6 h) increased IL-2
mRNA 3.6 þ 0.3-fold over control (lane 3). These
semi-quantitative measurements were carried out on
the Southern blots with similar results being obtained
from the quantitation of the RT-PCR products. The
level of IL-2 mRNA was normalised relative to the
aldolase mRNA in each sample. IRAK and TRAF-6
expression had no e¡ect on transcription of the con-
trol aldolase transcript (Fig. 4A,B). These results in-
dicated that both IRAK and TRAF-6 increase IL-2
gene transcription.
We also compared the stability of the mRNAs in
the di¡erent samples above to determine whether
there was a di¡erence in how they were regulated
post-transcriptionally. Control, IL-1-stimulated and
IRAK- or TRAF-6-transfected cells (5U106/ml)
were treated with actinomycin D (1 mM) to inhibit
new transcription. Total RNA was isolated 6 h post
treatment and RT-PCRs (Fig. 4A, lanes 2, 4, 6, 8)
followed by Southern blotting (Fig. 4B) were carried
out. The stability of the IL-2 mRNAs in each sample
was measured by calculating its decay after 6 h com-
pared to its accumulation prior to addition of the
transcription inhibitor. All values were normalised
to the aldolase signals. As already described the
steady state level of IL-2 mRNA was low in unsti-
mulated EL4.NOB-1 cells (lane 1); however, these
control levels decayed by 50 þ 7.1% (mean þ S.D.,
n = 3), following actinomycin D treatment, a repre-
sentative result being shown in Fig. 4A,B (lanes 1
and 2). The mRNA induced by IL-1 was stabilised,
however, with only 18.9 þ 8% decay (mean þ S.D.,
n = 3) under the conditions tested (Fig. 4B, lanes 3
and 4). In comparison, the IL-2 transcripts generated
as a result of IRAK (lanes 5 and 6) and TRAF-6
(lanes 7 and 8) overexpression were markedly de-
cayed over the same time period. This result meant
that the IL-2 mRNA induced by IL-1 was virtually
intact at 6 h following actinomycin D, but that in-
duced by IRAK- and TRAF-6-transfected cells had
degraded to less of the IL-2 mRNA in unstimulated
non-transfected cells.
In order to more rigorously measure the kinetics of
IL-2 mRNA decay in response to IL-1 treatment and
IRAK or TRAF-6 transfection, time course studies
using competitive PCR followed by quantitative mi-
crotitre plate measurement of IL-2 and control am-
plicons were carried out. IL-1-stimulated and IRAK-
or TRAF-6-transfected cells were treated with acti-
nomycin D, and total RNA was isolated at various
times up to 24 h. cDNA was synthesised using an
oligo(dT15) primer and its integrity was veri¢ed by
measuring the relative amounts of aldolase mRNA in
each sample by PCR using aldolase-speci¢c primers
(not shown). Competitive PCR reactions using bio-
tinylated IL-2-speci¢c primers were carried out using
a known quantity of exogenously synthesised IL-2
DNA, the ICS, mixed with the sample cDNA. Fol-
lowing PCR the amplicons were visualised by agar-
ose gel electrophoresis (not shown). The PCR prod-
ucts were denatured and hybridised to either ICS or
IL-2 sequence-speci¢c capture oligonucleotides
bound to microtitre wells and were detected and
quanti¢ed spectrophotometrically following addition
of an enzyme-streptavidin conjugate and substrate.
The signal generated in each reaction was propor-
tional to the amount of amplicon present. The ICS
served as a standard for IL-2 cDNA quantitation as
it was ampli¢ed at an e⁄ciency identical to the IL-2
cDNA. The number of copies of IL-2 in each PCR
reaction was calculated from the ratio of the total
optical density for the IL-2-speci¢c wells to the total
optical density for the ICS-speci¢c wells and the in-
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put copy number of the ICS. These results were ex-
pressed as relative IL-2 mRNA amounts. As shown
in Fig. 4C the relative amount of IL-2 mRNA gen-
erated following IL-1 treatment remaining after acti-
nomycin D treatment was 94 þ 3, 72 þ 2.5 and
59 þ 0.2% at 3, 6 and 24 h, respectively (mean þ S.D.,
n = 3). In contrast the IL-2 mRNAs generated in re-
sponse to IRAK or TRAF-6 transfection were con-
siderably less stable. The IL-2 mRNA generated fol-
lowing IRAK transfection decayed by 66 þ 1.7% at
3 h, and less than 1% remained after 24 h. TRAF-6-
induced IL-2 mRNA also decayed more rapidly then
the IL-1-induced IL-2 mRNA, with less than 8%
remaining 6 h post actinomycin D treatment. These
results con¢rm that IL-2 mRNA induced by IL-1 is
stabilised whilst that induced in IRAK- and TRAF-
6-transfected cells is unstable. IL-1 treatment, but
not IRAK or TRAF-6, can provide signal(s) that
stabilise IL-2 mRNA. Such signals must therefore
be essential for the e⁄cient translation of the IL-2
mRNA induced.
4. Discussion
Signi¢cant advances have been made recently in
elucidating components of the IL-1 signalling path-
way leading to NFUB activation, providing us with
an increased understanding of the molecular proc-
esses involved. IRAK, IRAK-2, TAB1/TAK1, NIK
and the IKKs represent an array of novel protein
kinases which signal in cooperation with novel signal
transducing molecules, TRAF-6 and MyD88, to co-
ordinate IL-1-stimulated intracellular responses
[5,8,12,13,15^23]. The involvement of these factors
has added an increased complexity to the emerging
picture of how IL-1 induces its pleiotropic biological
e¡ects. The expression of over 90 genes a¡ecting im-
mune and in£ammatory responses has been shown to
be a¡ected by IL-1 and an area of intense study has
been the receptor-mediated signal transduction path-
ways inducing such changes in gene expression.
Analysis of the cellular regulation of the newly char-
acterised factors will help to establish an even clearer
picture of how IL-1 signalling occurs. Experiments
described here were designed to investigate the in-
volvement of two IL-1 signal mediators, IRAK and
TRAF-6, in IL-1-induced responses in EL4.NOB-1 T
cells, namely induction of the IL-2 promoter, IL-2
mRNA and protein. We have found that IRAK
and TRAF-6 regulate the IL-2 gene, their primary
e¡ect being at the level of transcription. We provide
direct evidence that TRAF-6 lies downstream from
IRAK, and that TRAF-6 is critical for IRAK- and
IL-1-induced responses. We show that IL-1 controls
post-transcriptional regulation of IL-2 by providing
stabilisation signals for IL-2 mRNA which are re-
quired for IL-2 protein production. Such signals
are unlikely to involve IRAK or TRAF-6.
Most IL-1-responsive genes carry consensus se-
quences for NFUB in their promoters making it an
obvious target molecule to monitor when examining
IL-1-induced e¡ects. The elucidation of NIK as a
regulator of IKK1 and 2, the enzymes responsible
for phosphorylation of IUBK [21,22], has clearly de-
¢ned the molecular events which occur directly up-
stream from NFUB, with IRAK and TRAF-6 ap-
pearing to act in proximity to the membrane-
associated IL-1 receptor complex. The ability of
IRAK to induce NFUB-linked reporter gene expres-
sion in EL4.NOB-1 cells was not surprising consid-
ering the similar reports of both IRAK’s and IRAK-
2’s e¡ect on NFUB in other cell lines [5,13]. However,
the potency of its e¡ect on NFUB in the EL4.NOB-1
cells is of interest. The powerful activation of a
downstream target by IRAK even when expressed
at low levels indicates that it commands an apical
position in the pathway. The TRAF-6 e¡ect on
NFUB-mediated transcription was somewhat less
pronounced than that of IRAK, with higher plasmid
concentrations being needed to induce an optimal
response.
The IRAK transfection experiments also indicated
that large amounts of IRAK were toxic to the cells.
This was not seen when equivalent doses of TRAF-6
or vector were substituted, indicating that IRAK can
induce cell killing at high doses. IRAK contains a
death domain which could be responsible for gener-
ating death signals through associations with the
cell’s apoptotic machinery. Indeed, IL-1 has been
shown to induce cytotoxic e¡ects in certain cell types,
e.g. insulin-producing islet L cells [28]. This may be
accomplished by transducing a death signal through
IRAK.
Another surprising observation in IRAK-trans-
fected cells was the IL-1-independent phosphoryla-
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tion of IRAK seen following transfection, indicating
a sensitive sensing mechanism controlling activation
of IRAK in EL4.NOB-1 cells. Translocation of
IRAK to the IL-1 receptor complex occurs prior to
or independently of IRAK phosphorylation. As it
becomes associated with the receptor complex
IRAK becomes increasingly phosphorylated and si-
multaneously activated [29]. We speculate that over-
expression of IRAK from a constitutive CMV pro-
moter is responsible for the observed e¡ect.
Relatively small amounts of transfected IRAK
cDNA induced activation hinting at the existence
of a sensitive detector responsible for regulating
IRAK phosphorylation. Alternatively, IRAK over-
expression may induce spontaneous IL-1RI and IL-
1RAcp receptor aggregation thereby mimicking IL-1
engagement of its receptors.
The ability of IRAK and TRAF-6 to cause acti-
vation of NFUB in EL4.NOB-1 cells prompted fur-
ther analysis into what additional transcriptional ef-
fects IRAK or TRAF-6 could induce. Expression of
either protein had no e¡ect on an NFAT-linked re-
porter gene in the absence or presence of an IL-1
stimulus (data not shown). Expression of IRAK or
TRAF-6 induced the IL-2 promoter. This induction
was inhibited by cotransfection with a S32A/S36A
mutant of IUB which prevents NFUB activation
and showed that the IL-2 promoter is critically de-
pendent on NFUB. IRAK and TRAF-6 expression
also increased IL-2 mRNA production. However,
interestingly, neither IRAK nor TRAF-6 increased
IL-2 protein production. Nonetheless, this IL-1 re-
sponse was potentiated in cells overexpressing
IRAK and TRAF-6. A recent study in EL4 6.1 cells
stably transfected with IRAK gave a similar result
with regard to IL-2 protein production where the IL-
1 response was potentiated [30]. This indicated that
both IRAK and TRAF-6 were participating in the
pathway to IL-2 production but that their e¡ects
were primarily transcriptional.
Additional signals were shown to be induced by
IL-1 which have post-transcriptional e¡ects on the
IL-2 mRNA. These signals include stabilisation of
the IL-2 mRNA, an event which was not induced
by expression of IRAK or TRAF-6. Our initial in-
vestigations suggested that IL-1 treatment led to sta-
bilisation of the IL-2 transcript but that IRAK or
TRAF-6 expression failed to stabilise the IL-2
mRNA under the same conditions. Quantitative
competitive PCR con¢rmed this observation and
demonstrated that IL-2 mRNAs generated following
IRAK or TRAF-6 transfection were far less stable
than those induced by IL-1. This implied that neither
IRAK nor TRAF-6 can regulate processes involved
in IL-2 mRNA stabilisation. Such processes may in-
volve MAP kinases such as JNK or p38 MAP ki-
nase, and IRAK has been shown by others to regulate
both kinases [30^33]. JNK has been implicated in
stabilisation of IL-2 mRNA. However, this was not
examined in response to IL-1 stimulation [34]. Our
result implies that neither kinase is involved here or
alternatively that additional signals are needed which
are not activated by IRAK or TRAF-6.
Our previous report that IRAK and TRAF-6 in-
duce AP1-linked gene expression and potentiate the
e¡ect of IL-1 on this response suggests that IRAK
and TRAF-6 can integrate additional signals from
separate pathways [14]. These e¡ects on AP1 may
involve JNK. The TRAF-6-mediated activation of
both NFUB and AP1 in response to IL-1 is similar
to TNF-induced e¡ects on the TRAF2 signal trans-
ducer. TRAF2 represents the bifurcation point of
independent pathways which culminate in NFUB
and AP1 activation [35]. It is possible that TRAF-6
ful¢ls a similar role in transduction of the IL-1 signal
to distinct downstream e¡ectors. Alternatively,
TRAF-6 might mediate AP1 activation via NIK in
a JNK-independent manner similar to the TNFR1-
mediated TRAF2 pathway [35]. In B cells CD40-
mediated NFUB activation can occur by two di¡er-
ent mechanisms. One pathway involves TRAFs 2, 3
or 5 and requires the TIMct region of CD40 [10,36^
38] whereas the other is a TRAF-6-dependent mech-
anism and involves TRAF-6 recruitment to the ami-
no terminal end of CD40 [27]. Whether IRAK is
involved in this pathway is not known. Nonetheless
it appears that TRAF-6 may have a more general
function as an adaptor protein which participates
in di¡erent signalling pathways.
All of the responses tested in this study were
TRAF-6-dependent as shown by their inhibition fol-
lowing expression of TRAF-6v. Overexpression
studies have demonstrated the ability of TRAF-6v
to inhibit IRAK-2 induced NFUB activation [13];
however, no IL-1-dependent e¡ects were tested.
Here, similar to the report of TRAF-6 functioning
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downstream from Myd88 [39], we provide direct evi-
dence that TRAF-6 lies downstream from IRAK.
Previous evidence in this regard has been circumstan-
tial, as it has involved immunoprecipitations [8]. Un-
like IRAK, TRAF-6 does not co-immunoprecipitate
with IL-1RI. IRAK and TRAF-6 will co-immuno-
precipitate, however. Our results con¢rm the pro-
posed model that TRAF-6 lies downstream from
IRAK. Our results also show that TRAF-6 mediates
activation of the IL-2 promoter by both IRAK and
IL-1. TRAF-6v did not completely abolish the ef-
fects of IRAK or IL-1. It is likely therefore that
other signals participate in the responses mediated.
These can function when downstream targets of
TRAF-6 are not activated. The inhibitory e¡ect of
TRAF-6v on the IL-1-induced increase in IL-2 pro-
tein production clearly pointed to the importance of
TRAF-6 for IL-2 gene transcription activated by
IL-1.
As yet, apart from IL-1 the only other stimulus
identi¢ed which activates IRAK is IL-18 [40,41].
IL-18 signals NFUB activation through a receptor
that associates with IRAK in Th1 cells but which
is distinct from IL-1RI. This receptor has been sug-
gested to be IL-1Rrp, a homologue of IL-1RI [42].
Indeed, in EL-4 cells binding of IL-18 to this recep-
tor activates the IRAK-TRAF-6 pathway resulting
in NFUB activation [43]. Medzhitov et al. described
upregulation of NFUB-controlled genes by constitu-
tively active hToll (hTLR4) [44], also a member of
the IL-1 receptor family. hToll has been implicated
in the integration of innate immunity and induction
of adaptive responses [45] with IRAK and TRAF-6
participating in this response [46]. More recently hu-
man TLR2 and murine TLR4 have been shown to
mediate LPS signalling [47,48]. Therefore IRAK and
TRAF-6 are likely to be crucial signalling molecules
for other members of the IL-1 receptor family, in-
cluding the growing subset of human Toll-like recep-
tors (hTLRs) [49].
In conclusion, this study points to a critical role
for IRAK and TRAF-6 in regulation of IL-2 gene
expression. Their e¡ects are on transcription with
additional IL-1 signals being responsible for post-
transcriptional events, including mRNA stabilisa-
tion, leading to IL-2 protein production. Both
IRAK and TRAF-6 can therefore be added to the
list of signal transducers essential for T cell activa-
tion and are likely to be important regulators of in-
£ammation and innate immunity.
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